NovImmune raised €36M in a Series B round in Jun 2006. The company is based in Plan-les-Ouates, Switzerland. Investors in the round: Aravis Ventures, LODH Immunology Fund, Novartis Venture Fund and 1 other. Data as of 7 Aug 2026.
No source on record — unverified.
Confidence is the weaker of amount-FX and source evidence (the cascade rule). See methodology.
